Benevolent News Hub

“We need leaders with empathy who care about their fellow citizens and are prepared to work to end injustice and create opportunities for all". Our CEO Joanna Shields opens CogX 2020 sharing inspiration for the next decade.

To conclude Mental Health awareness week, we share some thoughts about the power of kindness and how building a culture of openness will help shape the future of business.

For Mental Health Awareness Week, BenevolentAI’s in-house yogis and bioinformaticians evaluated the scientific research behind the effect of yoga on mental health.

BenevolentAI announced that baricitinib is entering clinical testing as a potential COVID-19 treatment. Benevolent identified the drug using its AI drug discovery platform. The trial by Eli Lilly will investigate the drug’s efficacy and safety.

BenevolentAI today announced it has been selected for Tech Nation’s 2020 Future Fifty cohort. Our CEO Joanna Shields reflects on how joining forces with like-minded industry experts can serve as a powerful vehicle for transformation.

Our Senior Product Designer explores the design process at BenevolentAI where he builds user facing tools that help our scientists discover and develop new medicines.

For International Women’s Day we hosted a fireside chat with four of our female colleagues to learn about their experiences, successes and the challenges they've faced in a largely male dominated industry.

Sex differences have historically been neglected in clinical research, design and practice. For International Women’s Day, we explored the implications of this ‘one size fits all’ approach on women’s health.

The biomedical research data-gap risks worsening health inequality, and will be exacerbated in the age of AI. In a recent panel at Benevolent, technology and healthcare experts discussed the data diversity issue and proposed solutions.

We partnered with UC San Diego to investigate new approaches to develop non-invasive therapeutic treatments for CCM. Benevolent’s Senior Principal Scientist shares insights into his work to use AI to identify new targets associated with this disease.